Trial Search Results

Perfusion CT as a Predictor of Treatment Response in Patients With Rectal Cancer

A research study of rectal cancer perfusion (how blood flows to the rectum over time). We hope to learn whether perfusion characteristics of rectal masses may be predictive of response to treatment and whether rectal perfusion characteristics can be used to follow response to treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University




Inclusion Criteria:

   - Patients with suspected or biopsy-proven, locally advanced rectal cancer will be
   eligible for enrollment.

   - Patients must be 18 years or older. Patients must not be pregnant and, if of
   child-bearing age, must take precautions not to become pregnant.

   - No life expectancy restrictions.

   - ECOG and Karnofsky Performance Status will not be employed.

   - Patients with renal failure are ineligible for this study (GFR must be > 60)

   - Ability to understand and willingness to sign a written informed consent document.

Exclusion Criteria:

   - Patients who have undergone prior treatment for rectal cancer are ineligible for

   - No restrictions regarding use of other investigational agents.

   - Patients with severe contrast allergy are ineligible.

   - Patients who are pregnant or are trying to become pregnant are excluded from this

   - Patients who are cancer survivors or HIV-positive will not be excluded.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Laura Gable